Safi Mohammed, DO
Urology · Aurora, ILNPI 1891100889
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Coloplast at 39.4% of the total. Reporting peaked in 2024 at $6,084 and has fallen 77.4% since, to $1,373 in 2025.
Across 149 payments — averaging $89.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$5K
- Teleflex LLC$3K
- Boston Scientific$1K
- Olympus Winter & Ibe GmbH$875
- Medivators Inc.$500
- Astellas Pharma US Inc$306
- plus $2K from 25 others
What the payments were for
- Consulting fees$5,87544%
- Speaking & faculty fees$2,51419%
- Travel & lodging$6585%
- Food & beverage$4,19332%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 18 | $5,223 |
| Teleflex LLC | 18 | $3,374 |
| Boston Scientific | 29 | $1,451 |
| Olympus Winter & Ibe GmbH | 1 | $875 |
| Medivators Inc. | 1 | $500 |
| Astellas Pharma US Inc | 20 | $306 |
| Antares Pharma, Inc. | 20 | $298 |
| AbbVie(2 entities) | 3 | $185 |
| Neotract Inc. | 4 | $184 |
| Laborie Medical Technologies Corp. | 2 | $137 |
| Procept Biorobotics Corporation | 3 | $89 |
| Bluewind Medical | 1 | $70 |
| Intuitive Surgical | 2 | $64 |
| Ambu Inc. | 4 | $59 |
| Medtronic(2 entities) | 2 | $51 |
| Tolmar Pharmaceuticals, Inc. | 2 | $48 |
| Myriad Genetic Laboratories, Inc. | 2 | $48 |
| Blue Earth Diagnostics | 2 | $41 |
| Bayer | 2 | $30 |
| Richard Wolf Medical Instruments Corp. | 2 | $30 |
| Myovant Sciences Inc. | 1 | $28 |
| Amgen | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Axonics, Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| 180 Medical, Inc. | 1 | $15 |
| Rochester Medical Corporation | 1 | $15 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$2,000
- UroLift$1,330
- ENDOEYE FLEX DEFLECTABLE VIDEOSCOPE$875
- AMS$818
- BOTOX$144
- Optilume BPH Drug Coated Balloon Catheter$113
- XYOSTED$111
How this compares
$13,269 in reported general payments places this provider in the 85th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 68 | $53,269 |
| Tamsulosin Hcl | 1,020 | $13,833 |
| Finasteride | 663 | $8,021 |
| Oxybutynin Chloride | 184 | $2,815 |
| Solifenacin Succinate | 38 | $2,738 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,531 |
| Tolterodine Tartrate | 39 | $2,343 |
| Tadalafil | 21 | $2,278 |
| NitrofurantoinNitrofurantoin Macrocrystal | 49 | $1,776 |
| Oxybutynin Chloride ErOxybutynin Chloride | 86 | $1,751 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 161 | $1,288 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 57 | $1,237 |
| Cephalexin | 108 | $689 |
| Doxazosin Mesylate | 56 | $665 |
| Methenamine Hippurate | 16 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $306 | $53,26968 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 550 urology providers in Illinois.
Other urology in Aurora
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.